Lantern Pharma (LTRN) Status Update summary

Clinical trial progress and results

• Completed first-in-human phase I-A trial for LP-184, demonstrating favorable safety and tolerability, with most adverse events being manageable and no significant ocular toxicities observed.

• Achieved primary objectives, including establishing the recommended phase II dose and observing durable disease control in heavily pretreated patients, some exceeding 12 months on therapy.

• High prevalence of PTGR1 expression in patient tumors, supporting the precision medicine approach and biomarker-driven patient selection.

• Early anti-tumor activity observed in multiple solid tumor types, including triple-negative breast cancer, non-small cell lung cancer, and rare cancers, with notable responses in patients with DNA damage repair deficiencies.

• Phase I-B and phase II trials are planned, focusing on monotherapy and combination regimens in selected indications, using adaptive and Simon two-stage designs for rapid assessment.

Mechanism of action and scientific rationale

• LP-184 is a synthetic molecule inspired by illudin, designed for synthetic lethality in tumors with DNA damage repair deficiencies and high PTGR1 expression.

• Demonstrates strong selectivity for tumor cells due to PTGR1 overexpression and DNA repair pathway mutations, sparing normal cells.

• Effective in preclinical models against tumors with homologous recombination and nucleotide excision repair deficiencies, including those resistant to PARP inhibitors.

• Shows synergy with PARP inhibitors and potential to overcome resistance, with combination regimens planned for clinical trials.

• Crosses the blood-brain barrier, offering potential benefit in preventing or treating brain metastases, especially in triple-negative breast cancer.

Market potential and future directions

• LP-184 targets a large market, with significant potential in cancers harboring DNA repair deficiencies, estimated at up to 20-25% of all cancers.

• Holds three orphan and two fast-track designations, with opportunities for rapid regulatory advancement in indications like triple-negative breast cancer.

• Ongoing and planned trials include biomarker-driven studies in bladder cancer, combination regimens, and post-radiation strategies in pancreatic cancer.

• Over 10 patents issued or pending, with claims extending into the early 2040s, supporting long-term commercial potential.

• Strong safety profile and lack of cumulative toxicity enable prolonged dosing and support broad clinical exploration.